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Abstract
Rationale Pharmacological targeting of memory reconsolidation is a promising therapeutic strategy for the treatment of fear
memory-related disorders. However, the success of reconsolidation-based approaches depends upon the effective destabilisation
of the fear memory by memory reactivation.
Objectives Here, we aimed to determine the functional involvement of dopamine D1 receptors in cued fear memory
destabilisation, using systemic drug administration.
Results We observed that direct D1 receptor agonism was not sufficient to stimulate tone fear memory destabilisation to facilitate
reconsolidation disruption by the glucocorticoid receptor antagonist mifepristone. Instead, administration of the nootropic
nefiracetam did facilitate mifepristone-induced amnesia, in a manner that was dependent upon dopamine D1 receptor activation.
Finally, while the combined treatment with nefiracetam and mifepristone did not confer fear-reducing effects under conditions of
extinction learning, there was some evidence that mifepristone reduces fear expression irrespective of memory reactivation
parameters.
Conclusions The use of combination pharmacological treatment to stimulate memory destabilisation and impair reconsolidation
has potential therapeutic benefits, without risking a maladaptive increase of fear.
Keywords Reconsolidation . Destabilisation . Dopamine . Nefiracetam . Fear . Extinction .Mifepristone . Glucocorticoid
Introduction
The disruption of memory reconsolidation, the restabilisation
of a memory destabilised following retrieval, represents a
promising therapeutic approach for anxiety and trauma-
related disorders. Pharmacological impairment of memory
reconsolidation reduces fearful behaviour in rodents (Nader
et al. 2000), fear responses in experimental human studies
(Agren 2014) and clinical symptoms in patients suffering with
PTSD and phobias (Brunet et al. 2011; Soeter and Kindt
2015).
While the efficacy of reconsolidation impairment appears
relatively robust, targeting reconsolidation depends upon the
success of destabilising the memory behaviourally via a mem-
ory reactivation session, which usually takes the form of cue
re-exposure (Almeida-Correa and Amaral 2014). It is
increasingly evident that successful reconsolidation impair-
ment is far from guaranteed (Kindt and van Emmerik 2016),
especially as there are unpredictable boundary conditions that
govern memory destabilisation (Wideman et al. 2018). For
example, we recently demonstrated that there appears to be
no reliable basis upon which to predict the behavioural param-
eters that will trigger memory destabilisation/reconsolidation
(Cassini et al. 2017). In fact, lack of replicability of
reconsolidation impairments may well be due to poorly un-
derstood boundary conditions onmemory destabilisation (Bos
et al. 2014).
This lack of reliability of memory destabilisation raises the
potential that reconsolidation-disrupting pharmacological
treatment might be applied to individuals with no chance of
beneficial effect (because the memory has not been
destabilised and so there is no reconsolidation process to im-
pair). This has motivated the exploration of pharmacological
enhancement of memory destabilisation (Bustos et al. 2010;
Gazarini et al. 2015; Lee and Flavell 2014). Here, we further
explored the potential to enhance the destabilisation of cued
fear memories. In spite of recent promising results (Bustos
et al. 2010; Lee and Flavell 2014; Ortiz et al. 2015), we elected
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not to focus on D-cycloserine or ACEA as potentiators of
destabilisation, partly due to the fact that D-cycloserine can
enhance reconsolidation to strengthen fear (Lee et al. 2006)
and there remains a degree of uncertainty concerning the ef-
fects of CB1 receptor modulation on fear memory
reconsolidation (Lee et al. 2019; Lin et al. 2006; Ratano
et al. 2014). Moreover, given the potential use of NMDA
receptor and cannabinoid CB1 receptor antagonists for the
impairment of reconsolidation (Fattore et al. 2018; Stern
et al. 2012), separable pharmacological targets for
destabilisation enhancement and reconsolidation impairment
would be desirable. Therefore, we focussed on additional
mechanisms that have been implicated in memory
destabilisation, starting with the demonstration that dopami-
nergic signalling in the amygdala is necessary for appetitive
Pavlovian memory destabilisation (Merlo et al. 2015). As a
result, we tested whether dopamine D1 receptor agonism
would enhance cued fear memory destabilisation. Moreover,
we focussed on the use of the glucocorticoid antagonist mi-
fepristone for the impairment of reconsolidation (Pitman et al.
2011), given our initial failure to replicate published findings
with propranolol (Debiec and LeDoux 2004).
Materials and methods
Subjects
One hundred and eighty-eight male Lister Hooded rats
(Charles River, UK; 200–225 g at the start of the experiment)
were housed in quads under a 12-h light/dark cycle (lights on
at 0700) at 21 °C with food and water provided ad libitum
apart from during the behavioural sessions. The cages were
individually ventilated for the animals contributing to the data
in Figs. 1, 2, and 3, and were standard cages for the animals
contributing to the data in Fig. 4 (due to a facility equipment
change during the course of the project). The cages contained
aspen chip bedding, and environmental enrichment was avail-
able in the form of a Plexiglass tunnel. Experiments took place
in a behavioural laboratory between 0830 and 1300. At the
end of the experiment, the animals were humanely killed via a
rising concentration of CO2; death was confirmed by cervical
dislocation. Principles of laboratory animal care were follow-
ed, as approved by the University of Birmingham Animal
Welfare and Ethical Review Body and in accordance with
the United Kingdom Animals (Scientific Procedures) Act
1986, Amendment Regulations 2012 (PPLs P8B15DC34 &
P3B19D9B2).
Drugs
All drugs were administered systemically at previously
established doses and timepoints. Mifepristone (Generon,
UK) was injected at 30 mg/kg (60 mg/ml in propylene glycol,
s.c.) immediately after memory reactivation (Pitman et al.
2011). DL-propranolol (Sigma, UK) was injected at
10 mg/kg (10 mg/ml in saline, i.p.) immediately after reacti-
vation (Debiec and LeDoux 2004; Pitman et al. 2011). (+/−)-
SKF38393 (Sigma, UK) was injected at 5 mg/kg (5 mg/ml in
5% DMSO in saline, i.p.) 5 min before reactivation (de Lima
et al. 2011). Nefiracetam (Sigma, UK) was injected at 3 mg/kg
(6 mg/ml in saline, i.p.) 1 h before reactivation (Yoshii et al.
1997). SCH23390 (Tocris, UK) was injected at 0.1 mg/kg
(0.1 mg/ml in saline, i.p.) 30 min before reactivation (Heath
et al. 2015). Modafinil (Sigma, UK) was injected at 5 mg/kg
(10 mg/ml in 50% DMSO in saline, i.p.) 60 min prior to
reactivation (Shanmugasundaram et al. 2015). All i.p. injec-
tions were administered to the same (right) side of the abdo-
men. Allocation to drug treatment was fully randomised with-
in each experimental cohort of 8 rats.
Behavioural procedures
Rats were conditioned and tested individually in two identical
conditioning chambers (MedAssociates, VT) described previ-
ously (Lee et al. 2019). They were initially habituated to the
conditioning chamber for 1 h. On the next day, they received a
further 20-min habituation, followed by a single presentation
of a single 30-s, 1.5-kHz tone, co-terminating with a 1-s (or
0.5-s), 0.4-mA footshock. There was a 2-min recovery period
following the footshock delivery. Twenty-four hours after
training, the tone fear memory was reactivated by re-
presenting the tone once for 60 s (the longer duration aiming
to maximise prediction error) (Fernandez et al. 2016), after a
60-s pre-CS period. Twenty-four hours after reactivation, con-
ditioned freezing to the tone was assessed in a session identi-
cal to reactivation.
For the extinction experiment, all procedures were the
same (with the 1-s footshock delivery) apart from the session
24 h after training. Rats were exposed to ten 60-s tone presen-
tations, after a 60-s pre-CS period and with 60-s intervals
between each tone presentation (Lee et al. 2006).
Statistical analyses
Data are presented as% time freezing (+ SEM) during the pre-
CS period and tone presentation of the test. Nine subjects were
excluded from the extinction experiment analyses due to
equipment malfunction; 6 subjects were excluded as the pri-
mary endpoint was > 2 s.d. from the group mean. The data
were analysed in JASP (JASP Team 2016) by repeated-
measures ANOVAwith Group and Phase (pre-CS vs. CS pe-
riods) as factors, followed by analyses of simple main effects
of group at each phase. For the extinction experiment, the
analysis used nefiracetam and mifepristone as separate factors
in a 3-way repeated-measures ANOVA. Given the nature of
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the effects observed at test, additional analyses of the extinc-
tion session, as well as an exploratory ANCOVA (with per-
formance at extinction included as the covariate), were con-
ducted. The primary analyses were frequentist, with alpha =
0.05 and either Cohen’s d or η2p reported as an index of effect
size, and the data were initially checked for normality.
Significant group effects were explored with Tukey’s post-
hoc pairwise comparisons. We also report BFInclusion and
BF10 from parallel Bayesian analyses (Cauchy prior r =
0.707) as an estimate of posterior probability, with post-hoc
tests as appropriate.
Results
First, we showed that mifepristone, but not propranolol, was
effective at impairing tone fear memory reconsolidation.
Under weak single-trial conditioning parameters (0.5-s, 0.4-
mA footshock), immediate post-reactivation injection of mi-
fepristone, but not propranolol, impaired subsequent freezing
to the conditioned tone at test (Fig. 1a,b). With mifepristone,
there was a significant group × phase interaction (F(1,12) =
16.0, p = 0.002, η2p = 0.57, BFInc = 28.0), with a simple main
effect of group in freezing to the CS (t(12) = 2.42, p = 0.032,
d = 1.29, BF10 = 2.35), but not in the pre-CS period (t(12) =
0.63, p = 0.54, d = 0.34, BF10 = 0.51). In contrast, with pro-
pranolol, there were no group × phase interaction (F(1,12) =
0.66, p = 0.43, η2p = 0.05, BFInc = 1.74) and no main effect of
group (F(1,12) = 3.46, p = 0.08, η2p = 0.22, BFInc = 1.46).
Moreover, planned analyses of simple main effects of group
revealed no differences in freezing to the CS (t(12) = 1.03, p =
0.33, d = 0.55, BF10 = 0.63), although it was not absolutely
clear that there were no group differences in the pre-CS period
(t(12) = 2.15, p = 0.053, d = 1.15, BF10 = 1.7). The disruptive
effect of mifepristone was not replicated with stronger condi-
tioning (1.0-s, 0.4-mA footshock, Fig. 1c,d). Post-reactivation
injection of neither mifepristone nor propranolol had an effect
on subsequent tone freezing. There were no group × phase
interactions (mifepristone: F(1,12) = 0.041, p = 0.84, η2p =
0.003, BFInc = 0.61; propranolol: F(1,12) = 0.61, p = 0.81,
η2p = 0.005, BFInc = 0.67) or main effects of group (mifepris-
tone: F(1,12) = 0.066, p = 0.80, η2p = 0.005, BFInc = 0.61;
propranolol: F(1,12) = 0.73, p = 0.41, η2p = 0.06, BFInc =
0.58). Planned analyses of simple main effects confirmed no
Fig. 1 Systemic administration of
mifepristone, but not propranolol,
impaired the reconsolidation of
weak, but not strong, tone fear
memory. After conditioning with
a 0.5-s footshock, post-
reactivation mifepristone (a), but
not propranolol (b), impaired
conditioned freezing to the tone,
but not during the pre-CS period.
After conditioning with a 1-s
footshock, neither mifepristone
(c) nor propranolol (d) impaired
freezing during the pre-CS or tone
periods. Data presented as
mean + SEM (n = 7 per group)
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group differences in freezing to the CS (mifepristone: t(12) =
0.15, p = 0.89, d = 0.08, BF10 = 0.45; propranolol: t(12) =
0.75, p = 0.47, d = 0.40, BF10 = 0.54) or in the pre-CS period
(mifepristone: t(12) = 0.75, p = 0.89, d = 0.17, BF10 = 0.46;
propranolol: t(12) = 0.68, p = 0.51, d = 0.37, BF10 = 0.52).
Therefore, our stronger conditioning parameters represent a
boundary condition on tone fear memory reconsolidation, pre-
sumably under which our reactivation parameters were insuf-
ficient to destabilise the memory and render it vulnerable to
the amnestic effect of mifepristone.
Next, we tested whether pre-treatment with the D1R ago-
nist SKF38393 would facilitate memory destabilisation and
thereby render even the stronger tone fear memory vulnerable
to disruption by mifepristone. The combination of pre-
reactivation SKF38393 and post-reactivation mifepristone
had no effect on test tone freezing compared to both
SKF38393 + vehicle and vehicle + mifepristone (Fig. 2a;
group × phase: F(2,25) = 0.13, p = 0.88, η2p = 0.01, BFInc =
0.19; group: F(2,25) = 0.23, p = 0.80, η2p = 0.02, BFInc = 0.20;
simple main effect of group on CS freezing: F(2,25) = 0.03,
p = 0.97, η2p = 0.003, BFInc = 0.23; simple main effect of
group on pre-CS freezing: F(2,25) = 0.48, p = 0.62, η2p =
0.037, BFInc = 0.30). Numerical comparison with the previous
groups receiving vehicle or mifepristone alone indicates that
neither SKF38393 nor mifepristone in isolation had a disrup-
tive effect on subsequent tone freezing.
Fig. 3 Systemic administration of nefiracetam stimulated fear memory
destabilisation in a dopamine D1 receptor-dependent manner. After con-
ditioning with a 1-s footshock, pre-reactivation nefiracetam facilitated
disruption of tone, but not pre-CS, freezing by post-reactivation mifepris-
tone, when compared to mifepristone and nefiracetam alone (a; n = 7 per
group). When pre-reactivation treatment consisted of nefiracetam and
SCH23390, mifepristone no longer impaired tone or pre-CS freezing
(b; n = 8 per group). Data presented as mean + SEM
Fig. 2 Enhancement of dopaminergic signalling did not stimulate fear
memory destabilisation. After conditioning with a 1-s footshock, pre-
reactivation SKF38393 (a; ns = 13 [Veh +Mif], 7 [SKF +Mif] and 8
[SKF +Veh]) and modafinil (b; ns = 7 [Veh +Mif], 7 [Mod +Mif] and
8 [Mod +Veh]) did not facilitate disruption of tone, or pre-CS, freezing by
post-reactivation mifepristone, when compared to mifepristone and
SKF38393 or modafinil alone. Data presented as mean + SEM
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We also tested whether the less selective approach of
pre-treatment with the dopamine transporter blocker
modafinil would facilitate memory destabilisation. The
combination of pre-reactivation modafinil and post-
reactivation mifepristone had no effect on test tone freez-
ing compared to both modafinil + vehicle and vehicle +
mifepristone (Fig. 2b; group × phase: F(2,19) = 0.20,
p = 0.82, η2p = 0.02, BFInc = 0.35; group: F(2,19) = 1.06,
p = 0.37, η2p = 0.10, BFInc = 0.37; simple main effect of
group on CS freezing: F(2,19) = 0.73, p = 0.50, η2p =
0.071, BFInc = 0.39; simple main effect of group on pre-
CS freezing: F(2,19) = 0.75, p = 0.49, η2p = 0.073,
BFInc = 0.40). Numerical comparison with the previous
groups receiving vehicle or mifepristone alone again
indicated that neither modafinil nor mifepristone in isola-
tion had a disruptive effect on subsequent tone freezing.
Given that selective agonism of D1 dopamine receptors or
enhancement of dopaminergic neurotransmission did not ap-
pear to facilitate destabilisation, we adopted a broader spec-
trum approach, using the nootropic nefiracetam, which has
effects on not only monoaminergic systems (Luthman et al.
1994) but also cholinergic signalling (Oyaizu and Narahashi
1999) and calcium channels (Yoshii and Watabe 1994), both
of which have been implicated in memory destabilisation
(Stiver et al. 2015; Suzuki et al. 2008). The combination of
pre-reactivation nefiracetam and post-reactivation mifepris-
tone reduced test freezing (Fig. 3a; group: F(2,18) = 7.09,
p = 0.005, η2p = 0.44, BF10 = 6.0; phase × group: F(2,18) =
Fig. 4 Effects of pre-extinction
nefiracetam and post-extinction
mifepristone. After conditioning
with a 1-s footshock, nefiracetam
was injected systemically prior to
extinction and mifepristone im-
mediately after extinction. At test,
mifepristone reduced freezing to
the tone, while nefiracetam in-
creased freezing in both the pre-
CS and tone periods (a). While
there was no acute effect of pre-
extinction nefiracetam at the ex-
tinction session, there was a pre-
existing difference between the
groups subsequently administered
mifepristone compared to vehicle
(b). Data presented as mean ±
SEM (n = 8 per group)
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1.62, p = 0.23, η2p = 0.15, BFInc = 2.48). Analysis of simple
main effects confirmed reduced freezing in the nefiracetam +
mifepristone group to the tone compared to both nefiracetam +
vehicle and vehicle + mifepristone (F(2,18)=5.96, p = 0.010,
η2p = 0.40, BFInc = 5.6; post-hoc p < 0.05, BF10(Nef +Mif vs
Veh +Mif) = 2.2, BF10(Nef +Mif vs Nef + Veh) = 4.1). The latter two
groups froze at test at numerically higher levels to the vehicle
and mifepristone groups in the previous experiment (nef +
veh = 88.5 ± 3.3; veh + mif = 85.2 ± 5.8; veh = 71.1 ± 5.9;
mif = 69.4 ± 11.3), suggesting again that neither nefiracetam
nor mifepristone in isolation had a disruptive effect on subse-
quent tone freezing. Simple main effects revealed no signifi-
cant effect of group on freezing in the pre-CS period
(F(2,18) = 3.01, p = 0.074, η2p = 0.25, BF10 = 1.4; post-hoc
ps > 0.06, BF10(Nef + Mif vs Veh +Mif) = 1.9, BF10(Nef + Mif vs
Nef + Veh) = 1.3). However, as there was no strong evidence
for a selective effect on tone freezing and poor evidence that
nefiracetam +mifepristone did not impact upon pre-CS freez-
ing, we conducted an exploratory ANCOVA, with pre-CS
freezing as the covariate. This analysis confirmed the disrup-
tive effect of nefiracetam + mifepristone on tone freezing
(F(2,17) = 4.23, p = 0.032, η2p = 0.33, BFInc = 4.5).
While the mechanism of action of nefiracetam to facilitate
memory destabilisation remains unclear, we focussed again on
signalling at D1 dopamine receptors, testing whether such
signalling is necessary for the enhancement of memory
destabilisation. Co-pre-treatment with SCH23390 and
nef i racetam blocked the faci l i ta t ion of memory
destabilisation. A nefiracetam–SCH23390–mifepristone
group froze at higher levels at test relative to a nefiracetam–
vehicle–mifepristone comparison group (Fig. 3b). There was a
significant group × phase interaction (F(1,14) = 5.96, p =
0.029, η2p = 0.30, BFInc = 4.1), with a simple main effect of
group in freezing to the CS (t(14) = 2.48, p = 0.026, d = 1.24,
BF10 = 2.7), but not in the pre-CS period (t(14) = 0.88, p =
0.88, d = − 0.08, BF10 = 0.43).
Given that the neurochemical mechanisms of
destabilisation, reconsolidation and extinction overlap greatly
and that pharmacological approaches that impair
reconsolidation can also disrupt extinction to maintain fear
(Lee et al. 2006), we tested whether nefiracetam +mifepris-
tone, or either drug individually, would affect extinction learn-
ing/consolidation. Nefiracetam and mifepristone were admin-
istered at the same timepoints relative to the extinction session
as they had been in the previous reconsolidation experiments.
There was an effect of mifepristone to reduce freezing to the
tone, regardless of nefiracetam administration (Fig. 4a;
phase × mifepristone: F(1,28) = 7.92, p = 0.009, η2p = 0.22,
BFInc = 10.9; phase × nefiracetam × mifepristone: F(1,14) =
0.022, p = 0.88, η2p = 0.001, BFInc = 0.39), although it was not
clear that this effect of mifepristone on freezing to the tonewas
seen individually in both nefiracetam (phase × mifepristone:
F(1,14) = 4.36, p = 0.056, η2p = 0.24, BFInc = 1.54;
mifepristone on tone freezing: t(14) = 2.13, p = 0.051, d =
1.07, BF10 = 1.7; mifepristone on pre-CS freezing: (t(14) =
0.10, p = 0.92, d = 0.05, BF10 = 0.43) and vehicle
(phase × mifepristone: F(1,14) = 3.71, p = 0.075, η2p = 0.21,
BFInc = 1.88; mifepristone on tone freezing: t(14) = 2.43, p =
0.029, d = 1.22, BF10 = 2.5; mifepristone on pre-CS freezing:
(t(14) = 0.086, p = 0.93, d = 0.04, BF10 = 0.43) conditions.
Therefore, post-extinction mifepristone appears to reduce
freezing to the tone CS.
We also observed an effect of nefiracetam to increase test
freezing, irrespective of mifepristone administration
(nefiracetam: F(1,28) = 7.54, p = 0.010, η2p = 0.21, BFInc =
3.10; phase × nefiracetam: F(1,28) = 0.031, p = 0.86, η2p =
0.001, BFInc = 0.69). This effect was observed across both
tone (F(1,28) = 4.80, p = 0.037, η2p = 0.15, BFInc = 1.85) and
pre-CS (F(1,28) = 4.75, p = 0.038, η2p = 0.15, BFInc = 4.03)
periods. Further analysis suggested that the effect of
nefiracetam on tone freezing was observed more clearly in
mifepristone- (t(14) = 2.27, p = 0.039, d = 1.14, BF10 = 2.05)
than vehicle-treated rats (t(14) = 1.14, p = 0.28, d = 0.57,
BF10 = 0.65). Moreover, the effect of nefiracetam on pre-CS
freezing was not obvious when the two subgroups were
analysed independently (mifepristone: t(14) = 1.50, p = 0.16,
d = 0.75, BF10 = 0.89; vehicle: t(14) = 1.61, p = 0.13, d = 0.80,
BF10 = 0.98). Therefore, it remains unclear what is the major
factor underpinning the elevation of freezing with
nefiracetam.
Because the effect of nefiracetam appeared to occur wheth-
er or not mifepristone was subsequently administered, we
checked whether pre-extinction nefiracetam had an acute ef-
fect at the extinction session that might have persisted to the
test (Fig. 4b). Analysis of the pre-CS period at the extinction
session revealed no effect of nefiracetam or mifepristone
(nefiracetam × mifepristone: F(1,26) = 0.049, p = 0.83, η2p =
0.002, BFInc = 0.14; nefiracetam: F(1,26) = 0.014, p = 0.91,
η2p = 0.001, BFInc = 0.26; mifepristone: F(1,26) = 0.77, p =
0.39, η2p = 0.029, BFInc = 0.35). Analysis of freezing across
the 10 tone presentations revealed no evidence for an acute
effect of nefiracetam (tone × nefiracetam: F(2.6,66.6) = 0.96,
p = 0.41, η2p = 0.035, BFInc = 0.02; nefiracetam: F(1,26) =
0.23, p = 0.64, η2p = 0.009, BFInc = 0.15). However, the anal-
ysis also revealed that there potentially were pre-existing dif-
ferences at the extinction session between the groups subse-
quently administered with mifepristone (tone × mifepristone:
F(2.6,66.6) = 2.30, p = 0.095, η2p = 0.081, BFInc = 0.48; mi-
fepristone: F(1,26) = 0.89, p = 0.36, η2p = 0.033, BFInc =
0.30). Given that there appeared to be a small, albeit statisti-
cally non-significant, difference at the extinction session, we
conducted an exploratory ANCOVA in order to determine
whether the effect of mifepristone at test might be, at least in
part, caused by pre-existing group differences. This analysis
confirmed that, including freezing to the first tone at extinction
as a covariate, there remained a significant effect of
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mifepristone (F(1,25) = 7.06, p = 0.014, η2p = 0.22, BFInc =
5.14), as well as weaker evidence for an effect of nefiracetam
(F(1,25) = 4.62, p = 0.041, η2p = 0.16, BFInc = 1.85).
Because the question of importance is whether the puta-
tively beneficial therapeutic administration of nefiracetam and
mifepristone on destabilisation and reconsolidation might
have alternative, and perhaps negative, effects if behavioural
parameters promote extinction, we directly compared the
nefiracetam +mifepristone group against the vehicle + vehicle
group. There was little evidence for a reduction in tone freez-
ing (phase × group: F(1,14) = 3.73, p = 0.074, η2p = 0.21,
BFInc = 1.06; tone freezing: t(14) = 0.65, p = 0.53, d = 0.33,
BF10 = 0.49; pre-CS freezing: (t(14) = 1.55, p = 0.14, d = 0.77,
BF10 = 0.92). For consistency, we again conducted an explor-
atory ANCOVA, which confirmed no difference between the
groups (F(1,11) = 0.069, p = 0.80, η2p = 0.006, BFInc = 0.48).
Therefore, the potentially beneficial effect of mifepristone and
the contrasting negative effect of nefiracetam appear to inter-
act with co-administration of the two drugs to result in no
overall impact on freezing at test.
Discussion
Our results show evidence that the combination of pre-
reactivation systemic injection of nefiracetam and post-
reactivation systemic mifepristone reduced fear expression to
a fear conditioned tone. This disruptive effect was not ob-
served following administration of either drug alone or when
nefiracetam was replaced by either the D1 dopamine receptor
agonist SKF38393 or the dopamine receptor blocker
modafinil. However, co-administration of the D1 dopamine
receptor antagonist SCH23390 with nefiracetam and mifep-
ristone eliminated the disruption of fear memory expression.
The disruptive effect of nefiracetam and mifepristone was not
replicated when an extinction session was used instead of
memory reactivation. These results indicate that a combina-
tion treatment approach of nefiracetam to enhance memory
destabilisation and mifepristone to impair reconsolidation
may be effective for a reconsolidation-based treatment of fear
memory disorders, without the risk of potentially counterpro-
ductive effects on extinction. However, the precise mecha-
nism of action of the experimental amnesia induced by this
dual drug treatment remains unclear.
Systemic administration of mifepristone appeared to impair
the reconsolidation of cued fear memoires under various con-
ditions. We have previously used our current protocol to dem-
onstrate that systemic administration of the NMDA receptor
antagonis t MK-801 impaired cued fear memory
reconsolidation (Lee et al. 2006). Moreover, mifepristone
has previously been shown to impair the reconsolidation of
cued fear memories (Jin et al. 2007; Pitman et al. 2011), al-
though it has yet to be successfully translated to a human
clinical setting (Wood et al. 2015). While we did not include
a formal non-reactivation control condition (Dudai 2004), the
fact that mifepristone only disrupted freezing to the condi-
tioned tone under certain parametric conditions rules out
non-specific interpretations of the amnestic effect (see also
Cassini et al. 2017).
The failure of propranolol to impair fear memory expres-
sion at test under either of the two parametric conditions used
here is somewhat surprising, given the previous evidence that
propranolol does impair fear memory reconsolidation (Debiec
and LeDoux 2004; Kindt et al. 2009; Ortiz et al. 2015).
However, there are reports of failures to replicate the disrup-
tive effect of propranolol in fear memories (Bos et al. 2014;
Muravieva and Alberini 2010; Pitman et al. 2011), as well as
evidence that, at least in human studies, post-reactivation pro-
pranolol is less effective than pre-reactivation administration
in impairing fear memory reconsolidation (Thomas et al.
2017). Given that mifepristone and propranolol had differen-
tial effects under identical parametric conditions, it is unlikely
that the failure of propranolol here to disrupt fear memory
reconsolidation represents a boundary condition on memory
destabilisation. Therefore, it is perhaps more likely that the
post-reactivation timing, and systemic injection nature, of pro-
pranolol administration explains the lack of disruptive effect.
While it remains unclear why there was no evidence for an
impairing effect of propranolol, the advantageous effect of
mifepristone (see also Pitman et al. 2011) provided the basis
for further exploration.
Under the stronger fear conditioning parameters, pre-
reactivation systemic injection of nefiracetam rendered the
post-reactivation administration of mifepristone effective in
disrupting fear memory reconsolidation. The use of pre-
reactivation pharmacological adjunctive treatment to facilitate
reconsolidation impairments by other treatment has previous-
ly been demonstrated for stronger contextual fear memories
(Lee and Flavell 2014) and cued fear memories under condi-
tions of ethanol withdrawal (Ortiz et al. 2015) and prior stress
(Bustos et al. 2010). The common interpretation is that the
additional pharmacological treatment facilitates memory
destabilisation, rather than having an additive amnestic effect.
Indeed the use of the cannabinoid CB1 receptor agonist
ACEA (Lee and Flavell 2014) and the NMDA receptor partial
agonist D-cycloserine (Bustos et al. 2010; Ortiz et al. 2015) in
previous studies was predicated on prior evidence that CB1
and GluN2B receptors are necessary for memory
destabilisation (Ben Mamou et al. 2006; Suzuki et al. 2008).
The mechanism of action by which nefiracetam putatively
enhances fear memory destabilisation remains somewhat un-
clear. The aforementioned clear bidirectional effects of CB1
and NMDA (GluN2B) receptor modulation on memory
destabilisation (Ben Mamou et al. 2006; Lee and Flavell
2014; Ortiz et al. 2015; Suzuki et al. 2008) have not been
replicated here, in that the necessity for dopamine D1 receptor
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activation for cued fear memory destabilisation (Merlo et al.
2015) was not complemented here by any evidence that D1
receptor activation with SKF38393 is sufficient to enhance
destabilisation. This is in spite of further evidence in the cur-
rent study that D1 receptors are necessary for destabilisation
under our experimental conditions. Co-administration of
SCH23390 blocked the facilitative effect of nefiracetam, ren-
dering mifepristone ineffective at impairing reconsolidation.
This further suggests that D1 receptor activation is a neces-
sary, but not the sole functional mechanism of action of
nefiracetam to enhance destabilisation. It does not appear to
be the case that the insufficiency of D1 receptor activation
simply reflects the additional necessity of D2 receptor activa-
tion (Merlo et al. 2015), as the elevation of synaptic dopamine
levels by modafinil-induced blockade of the dopamine trans-
porter was similarly ineffective. This raises the question of
whether nefiracetam acts up- or down-stream of D1 receptor
activation. Acute administration of nefiracetam does elevate
monoamine (including dopamine) levels under certain condi-
tions (Luthman et al. 1994). However, nefiracetam also ap-
pears to augment intracellular memory-related processes to
facilitate memory consolidation (Doyle et al. 1996;
Nishizaki et al. 1998), raising the possibility that nefiracetam
might enhance subthreshold intracellular destabilisation pro-
cesses under boundary conditions of reconsolidation. The ef-
fect of co-administration of SCH23390 would then suggest
that the subthreshold intracellular destabilisation results from
an insufficient activation of D1 receptors, but this again is
inconsistent with the failure of SKF38393 to enhance
destabilisation.
The lack of effect of both SKF38393 and modafinil sug-
gests that there are non-dopaminergic mechanisms of action of
nefiracetam. One highly likely additional mechanism of action
is via L-type voltage-gated calcium channels (LVGCCs).
Blockade of LVGCCs with systemic injections of nimodipine
has been shown to prevent contextual fear memory
destabilisation (De Oliveira Alvares et al. 2013; Suzuki et al.
2008), and nefiracetam has pharmacological effects to en-
hance LVGCC calcium currents (Yoshii and Watabe 1994).
Therefore, we would predict that co-administration of
nimodipine would replicate the effect of SCH23390 to prevent
the enhancement of destabilisation by nefiracetam. A further
possibility is that nefiracetam acts though cholinergic recep-
tors, via an elevation of extracellular acetylcholine (Sakurai
et al. 1998). While cholinergic receptors have not to our
knowledge been studied in relation to fear memory
destabilisation, and dysregulation of cholinergic signalling
has instead been demonstrated to disrupt restabilisation
(Boccia et al. 2004; Boccia et al. 2006), activation of musca-
rinic acetylcholine receptors is sufficient to enhance
destabilisation of object recognition memories (Stiver et al.
2015). Moreover, it is possible that activation of nicotinic
acetylcholine receptors also contributes to object memory
destabilisation (Stiver et al. 2015), and, so, the identified ac-
tion of nefiracetam to elevate acetylcholine-induced currents
at nicotinic acetylcholine receptors (Oyaizu and Narahashi
1999) may contribute to the destabilisation of cued fear mem-
ories. However, perhaps the most likely mechanism of action
is via NMDA receptors, given the effect of nefiracetam to
potentiate NMDA receptor currents via interaction with the
glycine binding site (Moriguchi et al. 2003), allied with the
evidence that activation of NMDA receptors can facilitate
destabilisation (Bustos et al. 2010; Ortiz et al. 2015).
Given the complex mechanistic relationship between
destabilisation, reconsolidation and extinction (Almeida-
Correa and Amaral 2014; Cassini et al. 2017; Merlo et al.
2014), any potential therapeutic strategy that targets one of
these processes has the potential to result in “off-target” effects
on another process, leading to the possibility of maintaining or
even enhancing the problematic memory (Lee et al. 2006;
Tronson et al. 2006). Our results suggest that dual treatment
with nefiracetam and mifepristone does not disrupt or facili-
tate cued fear memory extinction. Importantly, this lack of
effect was observed under conditions that are appropriate for
engaging extinction (Lee et al. 2006) and not due to the pa-
rameters of extinction training falling into the “null” or “lim-
bo” space between destabilisation and extinction (Cassini
et al. 2017; Merlo et al. 2014). This assumption is supported
by the apparent effects of mifepristone and nefiracetam indi-
vidually. However, these individual effects of mifepristone
and nefiracetam indicate the need for caution when consider-
ing any translational application of the combined treatment.
The effect of nefiracetam to increase fear expression at test
and the suggestion that this increase in fear occurs even under
conditions of mifepristone administration indicate that pre-
extinction nefiracetam disrupts extinction learning and/or con-
solidation. This is a novel observation, as to our knowledge,
the effects of nefiracetam on extinction of any memory have
not previously been assessed. Such a disruption of extinction
contrasts with the apparent facilitation of destabilisation, and
as such may be inconsistent with the idea of a common
labilisation system (Almeida-Correa and Amaral 2014).
However, it remains possible that nefiracetam modulates
destabilisation and extinction via distinct mechanisms of ac-
tion, potentially at both pharmacological and neuroanatomical
levels. Regardless of the mechanism of action, the fear-
enhancing effect of nefiracetam alone raises concern that the
therapeutic strategy of using nefiracetam to facilitate
destabilisation might result in counterproductive effects on
extinction.
In contrast, the apparent effect of mifepristone to reduce
fear under conditions of extinction training further supports
its potential benefit. A treatment that reduces fear expression
irrespective of reactivation parameters would render that treat-
ment less dependent upon understanding the boundary condi-
tions of reconsolidation and extinction. However, it should be
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noted that the beneficial impact of mifepristone on extinction
was rather modest, and it remains unlikely that mifepristone
would have any effect in the “null point” between
reconsolidation and extinction. Moreover, while infusion of
mifepristone directly into the infralimbic cortex similarly en-
hanced the extinction of cued fear (Dadkhah et al. 2018), these
results contrast somewhat with previous observations show-
ing that intra-amygdala infusions of mifepristone did not di-
rectly affect extinction of fear-potentiated startle (Yang et al.
2006) and systemic injections of mifepristone did not affect
the extinction of contextual fear (Ninomiya et al. 2010).
Ultimately, there is a need to explore the effects of mifep-
ristone on extinction further, as well as determining the precise
mechanisms of action of nefiracetam to enhance
destabilisation and impair extinction. There is also the unan-
swered question of whether the apparent lack of effect of the
combination of nefiracetam and mifepristone on extinction
simply reflects the cancelling out of opposing effects.
Importantly, the persistence of the disruptive effect across both
reactivation and testing contexts is a key factor for translation-
al efficacy. Moreover, as the present study was conducted
exclusively on young male rats, there remains a need to deter-
mine whether the beneficial effects on fear memory expres-
sion generalise to other populations. However, the present
results support the premise that a strategy of enhancing
destabilisation and impairing reconsolidation via dual drug
treatment has the potential for reducing fear expression with-
out risking fear potentiation.
Acknowledgements The authors would like to thank David Barber for
technical support.
Funding and Disclosure This research was supported by a Leverhulme
Trust Research Project Grant to JL (RPG-2015-006).
Compliance with ethical standards
Conflict of interest On behalf of all authors, the corresponding author
states that there is no conflict of interest.
Human and animal rights and informed consent The experiments com-
ply with the United Kingdom Animals (Scientific Procedures) Act 1986,
Amendment Regulations 2012.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Agren T (2014) Human reconsolidation: a reactivation and update. Brain
Res Bull 105:70–82
Almeida-Correa S, Amaral OB (2014) Memory labilization in
reconsolidation and extinction—evidence for a common plasticity
system? J Physiol Paris 108:292–306
Ben Mamou C, Gamache K, Nader K (2006) NMDA receptors are crit-
ical for unleashing consolidated auditory fear memories. Nat
Neurosci 9:1237–1239
Boccia MM, Acosta GB, Blake MG, Baratti CM (2004) Memory con-
solidation and reconsolidation of an inhibitory avoidance response
in mice: effects of i.c.v. injections of hemicholinium-3.
Neuroscience 124:735–741
Boccia MM, Blake MG, Acosta GB, Baratti CM (2006) Post-retrieval
effects of icv infusions of hemicholinium in mice are dependent on
the age of the original memory. Learn Mem 13:376–381
Bos MG, Beckers T, Kindt M (2014) Noradrenergic blockade of memory
reconsolidation: a failure to reduce conditioned fear responding.
Front Behav Neurosci 8:412
Brunet A, Poundja J, Tremblay J, Bui E, Thomas E, Orr SP, Azzoug A,
Birmes P, Pitman RK (2011) Trauma reactivation under the influ-
ence of propranolol decreases posttraumatic stress symptoms and
disorder: 3 open-label trials. J Clin Psychopharmacol 31:547–550
Bustos SG, Giachero M, Maldonado H, Molina VA (2010) Previous
stress attenuates the susceptibility to midazolam's disruptive effect
on fear memory reconsolidation: influence of pre-reactivation D-
cycloserine administration. Neuropsychopharmacology 35:1097–
1108
Cassini LF, Flavell CR, Amaral OB, Lee JLC (2017) On the transition
from reconsolidation to extinction of contextual fear memories.
Learn Mem 24:392–399
Dadkhah M, Abdullahi PR, Rashidy-Pour A, Sameni HR, Vafaei AA
(2018) Infralimbic dopamine D2 receptors mediate glucocorticoid-
induced facilitation of auditory fear memory extinction in rats. Brain
Res 1682:84–92
de Lima MN, Presti-Torres J, Dornelles A, Scalco FS, Roesler R, Garcia
VA, Schroder N (2011)Modulatory influence of dopamine receptors
on consolidation of object recognition memory. Neurobiol Learn
Mem 95:305–310
De Oliveira Alvares L, Crestani AP, Cassini LF, Haubrich J, Santana F,
Quillfeldt JA (2013) Reactivation enables memory updating,
precision-keeping and strengthening: exploring the possible biolog-
ical roles of reconsolidation. Neuroscience 244:42–48
Debiec J, LeDoux JE (2004) Disruption of reconsolidation but not con-
solidation of auditory fear conditioning by noradrenergic blockade
in the amygdala. Neuroscience 129:267–272
Doyle E, O'Boyle KM, Shiotani T, Regan CM (1996) Nefiracetam (DM-
9384) reverses apomorphine-induced amnesia of a passive avoid-
ance response: delayed emergence of the memory retention effects.
Neurochem Res 21:649–652
Dudai Y (2004) The neurobiology of consolidations, or, how stable is the
engram? Annu Rev Psychol 55:51–86
Fattore L, Piva A, Zanda MT, Fumagalli G, Chiamulera C (2018)
Psychedelics and reconsolidation of traumatic and appetitive mal-
adaptive memories: focus on cannabinoids and ketamine.
Psychopharmacology 235:433–445
Fernandez RS, Boccia MM, Pedreira ME (2016) The fate of memory:
reconsolidation and the case of prediction error. Neurosci Biobehav
Rev 68:423–441
Gazarini L, Stern CA, Piornedo RR, Takahashi RN, Bertoglio LJ (2015)
PTSD-like memory generated through enhanced noradrenergic ac-
tivity is mitigated by a dual step pharmacological intervention
targeting its reconsolidation. Int J Neuropsychopharmacol:18
Heath FC, Jurkus R, Bast T, Pezze MA, Lee JL, Voigt JP, Stevenson CW
(2015) Dopamine D1-like receptor signalling in the hippocampus
and amygdala modulates the acquisition of contextual fear condi-
tioning. Psychopharmacology 232:2619–2629
JASP Team (2016) JASP
Psychopharmacology
Jin XC, Lu YF, Yang XF, Ma L, Li BM (2007) Glucocorticoid receptors
in the basolateral nucleus of amygdala are required for
postreactivation reconsolidation of auditory fear memory. Eur J
Neurosci 25:3702–3712
Kindt M, Soeter M, Vervliet B (2009) Beyond extinction: erasing human
fear responses and preventing the return of fear. Nat Neurosci 12:
256–258
Kindt M, van Emmerik A (2016) New avenues for treating emotional
memory disorders: towards a reconsolidation intervention for post-
traumatic stress disorder. Ther Adv Psychopharmacol 6:283–295
Lee JLC, Amorim FE, Cassini LF, Amaral OB (2019) Different temporal
windows for CB1 receptor involvement in contextual fear memory
destabilisation in the amygdala and hippocampus. PLoS One 14:
e0205781
Lee JLC, Flavell CR (2014) Inhibition and enhancement of contextual
fear memory destabilization. Front Behav Neurosci 8:144
Lee JLC,Milton AL, Everitt BJ (2006) Reconsolidation and extinction of
conditioned fear: inhibition and potentiation. J Neurosci 26:10051–
10056
Lin HC, Mao SC, Gean PW (2006) Effects of intra-amygdala infusion of
CB1 receptor agonists on the reconsolidation of fear-potentiated
startle. Learn Mem 13:316–321
Luthman J, Lindqvist E, Kojima H, Shiotani T, Tanaka M, Tachizawa H,
Olson L (1994) Effects of nefiracetam (DM-9384), a pyrrolidone
derivative, on brain monoamine systems. Arch Int Pharmacodyn
Ther 328:125–144
Merlo E, Milton AL, Goozee ZY, Theobald DE, Everitt BJ (2014)
Reconsolidation and extinction are dissociable and mutually exclu-
sive processes: behavioral and molecular evidence. J Neurosci 34:
2422–2431
Merlo E, Ratano P, Ilioi EC, Robbins MA, Everitt BJ, Milton AL (2015)
Amygdala dopamine receptors are required for the destabilization of
a reconsolidating appetitive memory(1,2). Eneuro 2
Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T (2003)
Potentiation of N-methyl-D-aspartate-induced currents by the noot-
ropic drug nefiracetam in rat cortical neurons. J Pharmacol Exp Ther
307:160–167
Muravieva EV, Alberini CM (2010) Limited efficacy of propranolol on
the reconsolidation of fear memories. Learn Mem 17:306–313
Nader K, Schafe GE, Le Doux JE (2000) Fear memories require protein
synthesis in the amygdala for reconsolidation after retrieval. Nature
406:722–726
Ninomiya EM, Martynhak BJ, Zanoveli JM, Correia D, da Cunha C,
Andreatini R (2010) Spironolactone and low-dose dexamethasone
enhance extinction of contextual fear conditioning. Prog Neuro-
Psychopharmacol Biol Psychiatry 34:1229–1235
Nishizaki T, Matsuoka T, Nomura T, Sumikawa K, Shiotani T, Watabe S,
Yoshii M (1998) Nefiracetam modulates acetylcholine receptor cur-
rents via two different signal transduction pathways. Mol Pharmacol
53:1–5
Ortiz V, Giachero M, Espejo PJ, Molina VA, Martijena ID (2015) The
effect of midazolam and propranolol on fear memory
reconsolidation in ethanol-withdrawn rats: influence of d-cycloser-
ine. Int J Neuropsychopharmacol 18:pyu082
Oyaizu M, Narahashi T (1999) Modulation of the neuronal nicotinic
acetylcholine receptor-channel by the nootropic drug nefiracetam.
Brain Res 822:72–79
Pitman RK, Milad MR, Igoe SA, Vangel MG, Orr SP, Tsareva A,
Gamache K, Nader K (2011) Systemic mifepristone blocks
reconsolidation of cue-conditioned fear; propranolol prevents this
effect. Behav Neurosci 125:632–638
Ratano P, Everitt BJ, Milton AL (2014) The CB1 receptor antagonist
AM251 impairs reconsolidation of Pavlovian fear memory in the
rat basolateral amygdala. Neuropsychopharmacology 39:2529–
2537
Sakurai T, Kato T, Mori K, Takano E, Watabe S, Nabeshima T (1998)
Nefiracetam elevates extracellular acetylcholine level in the frontal
cortex of rats with cerebral cholinergic dysfunctions: an in vivo
microdialysis study. Neurosci Lett 246:69–72
Shanmugasundaram B, Korz V, Fendt M, Braun K, Lubec G (2015)
Differential effects of wake promoting drug modafinil in aversive
learning paradigms. Front Behav Neurosci 9:220
Soeter M, Kindt M (2015) An abrupt transformation of phobic behavior
after a post-retrieval amnesic agent. Biol Psychiatry 78:880–886
Stern CA, Gazarini L, Takahashi RN, Guimaraes FS, Bertoglio LJ (2012)
On disruption of fear memory by reconsolidation blockade: evi-
dence from cannabidiol treatment. Neuropsychopharmacology 37:
2132–2142
Stiver ML, Jacklin DL, Mitchnick KA, Vicic N, Carlin J, O'Hara M,
Winters BD (2015) Cholinergic manipulations bidirectionally regu-
late object memory destabilization. Learn Mem 22:203–214
Suzuki A, Mukawa T, Tsukagoshi A, Frankland PW, Kida S (2008)
Activation of LVGCCs and CB1 receptors required for destabiliza-
tion of reactivated contextual fear memories. Learn Mem 15:426–
433
Thomas E, Saumier D, Pitman RK, Tremblay J, Brunet A (2017)
Consolidation and reconsolidation are impaired by oral propranolol
administered before but not after memory (re)activation in humans.
Neurobiol Learn Mem 142:118–125
Tronson NC, Wiseman SL, Olausson P, Taylor JR (2006) Bidirectional
behavioral plasticity of memory reconsolidation depends on
amygdalar protein kinase A. Nat Neurosci 9:167–169
Wideman CE, Jardine KH, Winters BD (2018) Involvement of classical
neurotransmitter systems in memory reconsolidation: focus on de-
stabilization. Neurobiol Learn Mem 156:68–79
Wood NE, Rosasco ML, Suris AM, Spring JD, Marin MF, Lasko NB,
Goetz JM, Fischer AM, Orr SP, Pitman RK (2015) Pharmacological
blockade of memory reconsolidation in posttraumatic stress disor-
der: three negative psychophysiological studies. Psychiatry Res 225:
31–39
Yang YL, Chao PK, Lu KT (2006) Systemic and intra-amygdala admin-
istration of glucocorticoid agonist and antagonist modulate extinc-
tion of conditioned fear. Neuropsychopharmacology 31:912–924
Yoshii M, Watabe S (1994) Enhancement of neuronal calcium channel
currents by the nootropic agent, nefiracetam (DM-9384), in NG108-
15 cells. Brain Res 642:123–131
Yoshii M, Watabe S, Sakurai T, Shiotani T (1997) Cellular mechanisms
underlying cognition-enhancing actions of nefiracetam (DM-9384).
Behav Brain Res 83:185–188
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Psychopharmacology
